Objective To assess the safety profile of slow-release (SR)The eÂect on supine blood pressure was minimal. In the subgroups of elderly and hypertensive patients alfuzosin in the treatment of benign prostatic obstruction (BPO), with special attention to orthostatic blood treated with SR alfuzosin, the cumulative incidence of asymptomatic orthostatic hypotension during the first pressure changes, postural symptoms and eÃcacy. Patients and methods Two placebo-controlled studies month of treatment was slightly higher than with placebo with no objective consequences on the inciinvolving 588 patients (292 receiving SR alfuzosin 5 mg twice daily and 296 a placebo) were pooled; dence of adverse events. The clinical eÃcacy of SR alfuzosin was confirmed by a significant improvement 51% of the patients were Á65 years of age and 43% had associated cardiovascular disease including hyperin urinary symptoms and a significant increase in maximum flow rates. tension and/or were receiving concomitant antihypertensive drugs.Conclusion SR alfuzosin (10 mg/day) can be administered safely without titration in patients with BPO, Results SR alfuzosin was very well tolerated with an overall incidence of adverse events similar to that of even in elderly and hypertensive patients. Its favourable benefit/risk ratio allows alfuzosin to be classified placebo (18.5% and 15.8% of patients, respectively) and an overall incidence of withdrawal from therapy as a clinically uroselective a 1 -blocker. Specific analysis of orthostatic changes in blood pressure is important for adverse events lower than that of placebo (3.4% and 5.7%, respectively). Adverse events potentially when assessing the safety profile of an a 1 -blocker in patients with BPO. related to vasodilatation were infrequent with SR alfuzosin (the same incidence as with placebo, i.e.Keywords Benign prostatic obstruction, slow-release alfuzosin, a 1 -blocker therapy, safety profile, clinical 2.7% of patients) and these adverse events occurred mainly during the first month of alfuzosin treatment.uroselectivity, orthostatic hypotension general practice [8]. In addition, besides improving LUTS Introduction and urodynamic variables, treatment with alfuzosin has a favourable impact on the quality of life of patients with The treatment of patients suÂering from benign prostatic obstruction (BPO) with a 1 -blocking agents is well estab-BPO [9]. Alfuzosin was initially available in Europe as an immediate-release formulation administered three lished and their eÂect on LUTS and urodynamics are assumed to be globally similar [1]. The main side-eÂects times daily. In fact, once-a-day and twice-a-day regimens have been shown to be associated with significantly associated with a 1 -blockers are postural symptoms relative to orthostatic hypotension, resulting from an impairbetter compliance (73% and 70%, respectively) than thrice-daily regimens (52%) [10]. In addition, the inciment of the compensatory reflex mechanism mediated by the sympathetic nervous system normally brought dence and severity of ...
The data for 19 patients with solitary plasmacytoma of the spine were reviewed with regard to clinical course and prognosis (median follow-up, 96 months). Eight patients presented with spinal cord compression. A monoclonal immunoglobulin was initially detected in seven of 15 evaluable patients. Treatment included radiotherapy (18 of 19) and/or surgery (11 of 19) and chemotherapy (eight of 19). Spinal cord compression was reversed in every patient. The expected survival rate was 85% at 10 years after diagnosis. Local recurrence or dissemination was observed in 13 patients. It occurred within 5 years of diagnosis in 11 patients and was localized (that is, local recurrence or single bone metastasis) in eight patients. It was always associated with the appearance or an increase of the M component. Dissemination frequently had a "metastatic" pattern with no diffuse bone marrow plasmacytosis. The incidence of local recurrence (five patients) and leukemia (four patients) was high. Local recurrence and/or dissemination were significantly more frequent in patients with the M component at diagnosis than in those without it (P less than 0.05; relative risk, R = 4). The effectiveness of surgery and chemotherapy combined with radiotherapy is also discussed.
In order to document further the onset of action of alfuzosin, a selective alpha-1 blocker, 93 symptomatic patients with benign prostatic hypertrophy were randomly allocated to a single oral dose of either alfuzosin 1.25 mg or 2.5 mg, or placebo, after a 1-week placebo lead-in period. The effects on flow rates were assessed 1 h 30 min after administration. Peak and mean flow rates were significantly increased in the alfuzosin groups, as compared with placebo, in a dose-dependent manner. After a single intake of placebo, the mean values of these 2 parameters showed little change. The effect on the cardiovascular system (heart rate and blood pressure) was mild. This study indicates that the action of alfuzosin is already present 1 h 30 min after administration.
In order to assess the efficacy and safety of alfuzosin, an alpha-1 blocker, in symptomatic patients with benign prostatic hyperplasia (BPH), 131 patients who had completed a 6-month placebo-controlled trial conducted on parallel groups entered a 12-month open study; 122 patients were treated with alfuzosin for 12 months and 56 patients for 18 months. After 12 months, all obstructive and irritative symptoms assessed according to the Boyarsky scale were significantly improved, as were peak flow rates in obstructed patients and mean flow rates and residual urine in the whole population. Voiding symptoms showed sustained improvement after treatment for 12 to 18 months. Only 5.3% of patients experienced vasodilatory side effects, none of which led to withdrawal from the study. No side effect related to long-term administration was reported. Alfuzosin has a beneficial effect on voiding symptoms in patients with BPH and can be safely used in long-term administration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.